(Q44148184)

30 November 2017

Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours (English)

1 reference

30 November 2017

1 reference

Muhammad Rohaizak

1

1 reference

PubMed ID

12269913

30 November 2017

John Richard Farndon

series ordinal

2

1 reference

30 November 2017

1 September 2002

1 reference

30 November 2017

ANZ Journal of Surgery

1 reference

30 November 2017

72

1 reference

30 November 2017

9

1 reference

30 November 2017

635-638

1 reference

The Cushing Syndrome Induced by Bronchial Carcinoid Tumors

30 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Substance P secretion by carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Flushing in the carcinoid syndrome and plasma kallikrein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

An analysis of 8305 cases of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Ueber den primären Krebs des Ileum nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberculose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Determination of 5-hydroxytryptamine, 5-hydroxyindole acetic acid and histamine in thirty-three cases of carcinoid tumor (argentaffinoma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Increased dopamine production in patients with carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Prostaglandins in amine-peptide-secreting tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

The Role of Interferons in the Management of Carcinoid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-2197.2002.02507.X

10.1046/J.1445-2197.2002.02507.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12269913